Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has made a 99.84% comeback from a 12-month low price of $48. It was seen 4.23% higher, changing the price to $64.05, when the closing bell rang on Oct. 16, 2017. At recent session, the prices were hovering between $63.45 and $64.15. This company shares are 11.05% off its target price of $71.13 and the current market capitalization stands at $2.38B. The recent change has given its price a 17.42% lead over SMA 50 and -3.1% deficit over its 52-week high. The stock witnessed 9.86% gains, 17.52% gains and 52.14% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AERI’s volatility during a week at 6.29% and during a month it has been found around 5.46%.
Aerie Pharmaceuticals, Inc. (AERI) Top Holders
Institutional investors currently hold around $2.12 billion or 99.72% in AERI stock. Look at its top three institutional owners. Adage Capital Partners Gp, L.L.C. owns $212 million in Aerie Pharmaceuticals, Inc., which represents roughly 8.91% of the company’s market cap and approximately 9.99% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 3,318,106 shares of the stock are valued at $203.9 million. The third largest holder is Blackrock Inc., which currently holds $159.94 million worth of this stock and that ownership represents nearly 6.72% of its market capitalization.
Aerie Pharmaceuticals, Inc. 13F Filings
At the end of June reporting period, 96 institutional holders increased their position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by some 7,277,192 shares, 78 decreased positions by 5,582,085 and 23 held positions by 21,683,632. That puts total institutional holdings at 34,542,909 shares, according to SEC filings. The stock grabbed 36 new institutional investments totaling 1,879,599 shares while 22 institutional investors sold out their entire positions totaling 1,233,713 shares.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insider Trades
Multiple company employees have indulged in significant insider trading. Aerie Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Foresite Capital Fund Ii, L.P. has sold 20,000 shares of Aerie Pharmaceuticals, Inc. (AERI) in trading session dated May. 26, 2017. These shares are worth $1,119,000 and were traded at $55.95 each. The SEC filing shows that Cagle Gerald D. performed a purchase of 1,000 shares. The Director added these shares by way of transaction on May. 09, 2017. The company’s shares were assimilated at $39.9 per share worth to an investment of some $39,900 on account of Cagle Gerald D..
Director, Cagle Gerald D., purchased 2,000 common shares of Aerie Pharmaceuticals, Inc. (AERI) in the open market. In a transaction dated Apr. 19, 2017, the shares were bought at an average price of $41.7, giving away a sum of $83,400. After this purchase, 11,900 common shares of AERI are directly owned by the insider, with total stake valued at $762,195.
In the transaction dated Feb. 15, 2017, the great number of shares disposed came courtesy the Director; Duyk Geoffrey M disposed a total of 41,591 shares at an average price of $46.63, amounting to approximately $1,939,388. The insider now directly owns 3,400 shares worth $217,770.
Aerie Pharmaceuticals, Inc. (AERI) Analyst Guide
Several analysts have released their opinion on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), with 4 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation.